Full-Time

Msl Cart – Cataluña

Posted on 10/31/2025

Deadline 11/7/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Scientific degree: Medical Doctor, Pharmaceutical or Nature Science university degree, or related qualification (i.e. psychology degree)
  • Deep knowledge of the therapeutic area, strength in research and interpretation of medical data
  • Background to be accepted by the Leading Specialists in peer-to-peer relationship, i.e. relevant work experience, scientific acumen and/or communication skills.
  • Highly customer focused with an awareness of the importance of business results
  • Innovative with the ability to coordinate and drive a complex and changing environment
  • Awareness of, and adherence to, Johnson & Johnson Credo values and International Health Care Business Integrity Guide.
  • Deep scientific knowledge in the therapeutic area
Responsibilities
  • To keep abreast of medical and scientific knowledge.
  • Continuous update on products, patient’s treatment trends, clinical activities and studies conducted within the therapeutic area in their region.
  • Development and maintenance of a contact network with Leading Specialists.
  • Understand their needs, key value drivers, practical treatment patterns and scientific activities within therapeutic area
  • Communicate value of company products, incl. clinical questionnaire discussions
  • Through scientific interactions, communicate medical benefits of products and contribute to foster innovative approaches
  • Represent the company within professional associations in the therapeutic area in cooperation with Medical Affairs/ Medical Education and other positions in the Medical Affairs Department
  • Proactive and reactive communication of medical scientific data according to following criteria
  • Proactive Scientific Communication to Leading Specialists must be consistent with the last approved Summary of Product Characteristics regarding the safe and effective use of approved products in approved indications. Content of Scientific Communication should be highly scientific, accurate, fair and objective, based on an up-to-date evaluation of all relevant evidence and reflect that evidence clearly, using neither marketing claims nor brand name.
  • In some very specific circumstances, the MSL can interact proactively with non-Leading Specialists. The program should be clearly defined in the MSL Country Activity Plan, providing the rational, the objective, content, timelines and selection criteria of the HCPs to be involved.
  • Description of R&D programs and discussing regulatory developments with no promotional intent are also part of Scientific Communication.
  • Reactive Communication of medical scientific data can be provided upon request to any Health Care Professional, within the approved label or off-label. The request should come either directly from the HCP or via the Medical Information department. MSLs are required to document all off-label information requests they receive from Leading Specialists and other HCPs that they may interact with.
  • Organization and participation in Medical Education activities, at local &/regional level:
  • Identify/support/educate speakers
  • Build Medical Education programs with scientific third party
  • Collaborate with Medical Education manager in National Medical education activities
  • Provide scientific material under request. MSLs may initiate discussion with potential speakers, discussing documents/ slides which may be of help for future presentations.
  • Organization and participation in Advisory Boards in cooperation with Medical Affairs/Medical Education/other positions in the Medical Affairs Department.
  • Market Access Discussions
  • MSLs can present highly scientific, accurate, fair and objective data to Payors (Hospital Formulary Committees, Health Insurers, Health Technology Assessment Committees, etc) to provide them with objective information about Company products.
  • Pre- Approval Activities
  • MSLs can engage in interactions with Payors to raise awareness so that payors can plan and budget so that patients can receive the product when it becomes available. MSLs can organize Speakers training to prepare speakers for delivering presentations to other HCP when the Marketing Authorization is granted.
  • Provision of scientific support to company Sales Representatives and other company representatives
  • Provide medical and product training and scientific support to Sales Representatives in coordination with Training/Medical Affairs Department as appropriate
  • Act as a reference point to Sales Representatives for any scientific query, in collaboration with Medical Information as appropriate.
  • Local implementation of Medical Affairs Plan in their areas:
  • Support the set up and follow up of local company sponsored studies, registries and other non-interventional Medical Affairs studies
  • Propose investigators and sites for interventional and non-interventional Medical Affairs studies.
  • Participate in investigator meetings preparation, recruitment follow-up and study result presentation.
  • Receive investigator proposals for IIS and ensure they are discussed within the Medical Affairs department for decision.
  • Through scientific interactions, gain valuable insight into treatment patterns and scientific activities in the therapeutic area and provide input and a strategic view to the company Medical Affairs Plan / business decision-making.
  • Observes and promotes all regulatory requirements as defined in applicable regulations, rules and procedures established by the Company, including but not limited to Health Care Business Integrity and Pharmacovigilance
  • Follow principles, procedures and training included in SAFE Fleet program.
  • GCO collaboration: Support GCO studies when needed through the identification of potential sites and facilitating a direct contact with leading specialists.
  • Report all suspected adverse reactions, serious or non serious, I may be aware of within a maximum of 24 hours after being aware of it and communicate it to the Pharmacovigilance Department.
  • Additionally, for all employees involved in Research Related Activities (RRA):
  • Ensure safety reporting requirements (timely AE/PQC reporting) as set out in company policies and SOPs (Standard Operating Procedures) are met and appropriately managed when planning projects, developing materials, executing projects and contracting vendors.
  • Ensure HCC and legal requirements (Fair Market Value, Transfer of Value rules, Promotional Materials rules) are fully understood, appropriately managed and complied with when planning projects, developing materials, executing projects and contracting vendors.
  • Ensure inspection readiness with respect to personal training compliance, and availability of recent CV and individualized Job Description.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE